• 30 Sep 19

Synairgen's phase II trial on lead COPD drug 'progressing well'

Synairgen's phase II trial on lead COPD drug 'progressing well'

Synairgen plc | SYGGF | 0 0 0%

    • 202 views

 

Synairgen PLC's (LON:SNG) Richard Marsden tells Proactive London's Andrew Scott  the respiratory drug discovery and development company, is well-poised to complete the phase II trial on its lead candidate.

The trial is expected to complete dosing in Q1 next year with results available in the second quarter.

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via our Refer a Friend page. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

Synairgen CEO on funding critical Phase 2 trial for SNG001

Companies: Synairgen plc

Synairgen to start trials this week of its lead drug in patients with COVID-19

Companies: Synairgen plc

Synairgen makes progress in H1 as it moves towards phase II trial of lead asset

Companies: Synairgen plc

Synairgen CEO details expansion of key coronavirus trial to patients in home

Companies: Synairgen plc

Synairgen provides update on progress during 2023

Companies: Synairgen plc

Synairgen's Richard Marsden details expansion of home-based coronavirus trial

Companies: Synairgen plc

© Research Tree 2025

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top